Somatostatin inhibits intestinal mucosal mast cell degranulation in normal conditions and during mast cell hyperplasia.
Several studies demonstrate that intestinal mucosal mast cells (IMMC) are modulated by nervous reflexes as well as by intraluminal content. We recently demonstrated that peptones, such as ovalbumin hydrolysate (OVH), induce the release of rat mast cell protease II (RMCP II), indicating IMMC degranulation. The response is due to complex neuroendocrine reflexes. Somatostatin (SS) and its analogues have been used as potential treatments for inflammation in other body systems with contradictory results. The aim of this study was to evaluate if somatostatin could contribute to the reduction of intestinal mucosal mast cell degranulation. Anesthetized rats were prepared for duodenal perfusion and mast cell activation was measured by analysis of RMCP II concentration in the duodenal perfusate. Somatostatin significantly decreased RMCP II concentration in both nonstimulated conditions and after ovalbumin hydrolysate perfusion. However, when somatostatin was given previously to OVH, the peptone still induced a slight increase of RMCP II. Similar effects were observed in animals previously treated with capsaicin. These protocols were repeated in animals infected with Trichinella spiralis, which induces mucosal mast cell hyperplasia. In these cases, somatostatin blocked the effect of OVH, thus, preventing an increase in RMCP II concentration. Fresh frozen tissue sections from the duodenum were processed in an attempt to demonstrate the presence of SS receptors in mast cells using immunofluorescence and Fluo-peptide labeling techniques. Confocal images from duodenum specimens demonstrate the existence of SS receptors in positive cells for RMCP II. Taken together, these results indicate that somatostatin diminishes mast cell activity and in consequence could prevent the intestinal responses to mast cell hyperplasia.
Saavedra
Y
Y
Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Spain.
Vergara
P
P
D000818:Animals; D002211:Capsaicin / Q000494:pharmacology; D015550:Cell Degranulation / Q000187:drug effects*; D002645:Chickens; D004386:Duodenum / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D005455:Fluorescent Antibody Technique; D006965:Hyperplasia; D007413:Intestinal Mucosa / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D008297:Male; D008407:Mast Cells / Q000187:drug effects / Q000469:parasitology / Q000502:physiology*; D018613:Microscopy, Confocal; D010047:Ovalbumin / Q000032:analysis / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010461:Peptones / Q000494:pharmacology; D011492:Protein Hydrolysates / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017481:Receptors, Somatostatin / Q000378:metabolism; D012697:Serine Endopeptidases / Q000032:analysis / Q000378:metabolism; D013004:Somatostatin / Q000494:pharmacology*; D017160:Trichinella spiralis; D014235:Trichinellosis / Q000473:pathology
D010461:Peptones; D011492:Protein Hydrolysates; D017481:Receptors, Somatostatin; D013004:Somatostatin; D010047:Ovalbumin; D012697:Serine Endopeptidases; D002211:Capsaicin